$111.99
Price
$8.7B
Market Cap
—
P/E Ratio
-20.0
Forward P/E
$-5.33
EPS (TTM)
—
Dividend Yield
$943M
Cash
—
Total Debt
72M
Shares Out
$55.53
$113.02
52-Week Range
Institutional Ownership of NUVALENT INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for NUVALENT INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2022-Q3 | |||||
| SELL | EXIT | — | — | $16.77 | |
| 2022-Q2 | |||||
| SELL | -32.6% | 1.1M | $15M | $10.30 | |
| 2021-Q3 | |||||
| BUY | NEW | 1.6M | $37M | $27.14 | |
Insider Trading for NUVALENT INC
6 Months Insider Sentiment
Buy $0
Sell $8.2M
0
Buys
49
Sells
-8.2M
Net
7
Grants
Largest
$798K
Porter
$770K
Balcom
$550K
Miller
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 07, 2026 | James Richard Porter | President and CEO | GRANT | 46.2K | — | — |
| Jan 07, 2026 | Darlene Noci | Chief Development Officer | GRANT | 17.5K | — | — |
| Jan 07, 2026 | Deborah Ann Miller | Chief Legal Officer | GRANT | 17.5K | — | — |
| Jan 07, 2026 | Christopher Durant Turner | Chief Medical Officer | GRANT | 17.5K | — | — |
| Jan 07, 2026 | Henry E. Pelish | Chief Scientific Officer | GRANT | 17.5K | — | — |
| Jan 07, 2026 | Alexandra Balcom | Chief Financial Officer | GRANT | 17.5K | — | — |
| Jan 06, 2026 | Henry E. Pelish | Chief Scientific Officer | SELL | 1.4K | $97.33 | $133K |
| Jan 06, 2026 | Henry E. Pelish | Chief Scientific Officer | SELL | 1.1K | $96.75 | $107K |
| Jan 06, 2026 | Henry E. Pelish | Chief Scientific Officer | SELL | 189 | $98.40 | $19K |
| Jan 06, 2026 | James Richard Porter | President and CEO | SELL | 675 | $98.40 | $66K |
| Jan 06, 2026 | Alexandra Balcom | Chief Financial Officer | SELL | 225 | $98.40 | $22K |
| Jan 06, 2026 | Alexandra Balcom | Chief Financial Officer | SELL | 1.3K | $96.75 | $128K |
| Jan 06, 2026 | Christopher Durant Turner | Chief Medical Officer | SELL | 225 | $98.40 | $22K |
| Jan 06, 2026 | Christopher Durant Turner | Chief Medical Officer | SELL | 1.3K | $96.75 | $128K |
| Jan 06, 2026 | Deborah Ann Miller | Chief Legal Officer | SELL | 183 | $98.40 | $18K |
| Jan 06, 2026 | Deborah Ann Miller | Chief Legal Officer | SELL | 1.1K | $96.75 | $104K |
| Jan 06, 2026 | Deborah Ann Miller | Chief Legal Officer | SELL | 1.3K | $97.33 | $130K |
| Jan 06, 2026 | Christopher Durant Turner | Chief Medical Officer | SELL | 1.6K | $97.33 | $159K |
| Jan 06, 2026 | Alexandra Balcom | Chief Financial Officer | SELL | 1.6K | $97.33 | $159K |
| Jan 06, 2026 | James Richard Porter | President and CEO | SELL | 4.9K | $97.33 | $477K |
| Jan 06, 2026 | Darlene Noci | Chief Development Officer | SELL | 225 | $98.40 | $22K |
| Jan 06, 2026 | Darlene Noci | Chief Development Officer | SELL | 1.3K | $96.75 | $128K |
| Jan 06, 2026 | Darlene Noci | Chief Development Officer | SELL | 1.6K | $97.33 | $159K |
| Jan 06, 2026 | James Richard Porter | President and CEO | SELL | 4.0K | $96.75 | $383K |
| Jan 05, 2026 | Henry E. Pelish | Chief Scientific Officer | SELL | 1.1K | $97.96 | $111K |
| Jan 05, 2026 | Alexandra Balcom | Chief Financial Officer | SELL | 317 | $98.52 | $31K |
| Jan 05, 2026 | Alexandra Balcom | Chief Financial Officer | SELL | 871 | $96.06 | $84K |
| Jan 05, 2026 | Alexandra Balcom | Chief Financial Officer | SELL | 1.1K | $96.85 | $108K |
| Jan 05, 2026 | Alexandra Balcom | Chief Financial Officer | SELL | 1.9K | $97.96 | $189K |
| Jan 05, 2026 | Christopher Durant Turner | Chief Medical Officer | SELL | 317 | $98.52 | $31K |
| Jan 05, 2026 | Christopher Durant Turner | Chief Medical Officer | SELL | 871 | $96.06 | $84K |
| Jan 05, 2026 | Christopher Durant Turner | Chief Medical Officer | SELL | 1.1K | $96.85 | $108K |
| Jan 05, 2026 | Christopher Durant Turner | Chief Medical Officer | SELL | 1.9K | $97.96 | $189K |
| Jan 05, 2026 | Darlene Noci | Chief Development Officer | SELL | 317 | $98.52 | $31K |
| Jan 05, 2026 | Darlene Noci | Chief Development Officer | SELL | 871 | $96.06 | $84K |
| Jan 05, 2026 | Darlene Noci | Chief Development Officer | SELL | 1.1K | $96.85 | $108K |
| Jan 05, 2026 | Darlene Noci | Chief Development Officer | SELL | 1.9K | $97.96 | $189K |
| Jan 05, 2026 | Deborah Ann Miller | Chief Legal Officer | SELL | 326 | $98.52 | $32K |
| Jan 05, 2026 | Deborah Ann Miller | Chief Legal Officer | SELL | 897 | $96.06 | $86K |
| Jan 05, 2026 | Deborah Ann Miller | Chief Legal Officer | SELL | 1.2K | $96.85 | $112K |
| Jan 05, 2026 | Deborah Ann Miller | Chief Legal Officer | SELL | 2.0K | $97.96 | $195K |
| Jan 05, 2026 | Henry E. Pelish | Chief Scientific Officer | SELL | 186 | $98.52 | $18K |
| Jan 05, 2026 | Henry E. Pelish | Chief Scientific Officer | SELL | 513 | $96.06 | $49K |
| Jan 05, 2026 | Henry E. Pelish | Chief Scientific Officer | SELL | 660 | $96.85 | $64K |
| Jan 05, 2026 | James Richard Porter | President and CEO | SELL | 1.3K | $98.52 | $132K |
| Jan 05, 2026 | James Richard Porter | President and CEO | SELL | 3.7K | $96.06 | $353K |
| Jan 05, 2026 | James Richard Porter | President and CEO | SELL | 4.7K | $96.85 | $458K |
| Jan 05, 2026 | James Richard Porter | President and CEO | SELL | 8.1K | $97.96 | $798K |
| Jan 02, 2026 | Deborah Ann Miller | Chief Legal Officer | SELL | 4.0K | $100.03 | $401K |
| Jan 02, 2026 | Deborah Ann Miller | Chief Legal Officer | EXERCISE | 10.0K | $18.93 | $189K |
| Jan 02, 2026 | Deborah Ann Miller | Chief Legal Officer | SELL | 5.5K | $100.77 | $550K |
| Jan 02, 2026 | Deborah Ann Miller | Chief Legal Officer | SELL | 540 | $101.47 | $55K |
| Dec 30, 2025 | Darlene Noci | Chief Development Officer | SELL | 642 | $101.22 | $65K |
| Dec 30, 2025 | Darlene Noci | Chief Development Officer | EXERCISE | 4.0K | $27.85 | $111K |
| Dec 30, 2025 | Darlene Noci | Chief Development Officer | SELL | 3.4K | $99.82 | $335K |
| Dec 22, 2025 | Alexandra Balcom | Chief Financial Officer | EXERCISE | 34.5K | $1.08 | $37K |
| Dec 22, 2025 | Henry E. Pelish | Chief Scientific Officer | EXERCISE | 5.1K | $1.08 | $5K |
| Dec 19, 2025 | James Richard Porter | President and CEO | EXERCISE | 57.0K | $0.65 | $37K |
| Dec 10, 2025 | Ron Squarer | Director | GRANT | 2.8K | — | — |
| Dec 08, 2025 | Alexandra Balcom | Chief Financial Officer | SELL | 7.0K | $110.31 | $770K |
| Dec 08, 2025 | Alexandra Balcom | Chief Financial Officer | SELL | 100 | $111.32 | $11K |